Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Hum Fertil (Camb) ; 9(3): 175-80, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17008270

RESUMEN

Ovarian hyperstimulation syndrome (OHSS) is a serious and potentially life-threatening complication following ovarian stimulation for in vitro fertilization (IVF). Coasting is the practice whereby the gonadotrophins are withheld and the administration of human chorionic gonadotrophin (hCG) is delayed until serum oestradiol (E2) has decreased to what is considered to be a safe level, to prevent the onset of OHSS. This study aimed to assess the length of coasting on the reproductive outcome in women at risk of developing OHSS. Coasting was undertaken when the serum E2 concentrations were > or = 17000 pmol/L but < 21000 pmol/L. Daily E2 measurements were performed and hCG was administered when hormone levels decreased to < 17000 pmol/L. Eighty-one women who had their stimulation cycles coasted were grouped according to the number of coasting days. Severe OHSS occurred in one case, which represented 1.2% of patients who underwent coasting because of an increased risk of developing the syndrome. No difference was found between cycles coasted for 1 - 3 days and cycles coasted for > or = 4 days in terms of oocyte maturity, fertilization and embryo cleavage rates. Women in whom coasting lasted for > or = 4 days had significantly fewer oocytes retrieved (P < 0.05) and decreased implantation rate (P < 0.05) compared to those coasted for 1 - 3 days. Pregnancy rate/embryo transfer and live birth rate did not differ between groups. In conclusion, coasting appears to decrease the risk of OHSS without compromising the IVF cycle pregnancy outcome. Prolonged coasting is, however, associated with reduced implantation rates, perhaps due to the deleterious effects on the endometrium rather than the oocytes.


Asunto(s)
Fertilización In Vitro/efectos adversos , Fertilización In Vitro/métodos , Síndrome de Hiperestimulación Ovárica/prevención & control , Gonadotropina Coriónica/administración & dosificación , Protocolos Clínicos , Estradiol/sangre , Femenino , Hormona Liberadora de Gonadotropina/agonistas , Humanos , Menotropinas/administración & dosificación , Síndrome de Hiperestimulación Ovárica/etiología , Embarazo , Resultado del Embarazo , Estudios Retrospectivos , Factores de Riesgo , Inyecciones de Esperma Intracitoplasmáticas/efectos adversos , Inyecciones de Esperma Intracitoplasmáticas/métodos , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA